The  ||| S:0 E:4 ||| DT
tumoral  ||| S:4 E:12 ||| NN
A  ||| S:12 E:14 ||| DT
genotype  ||| S:14 E:23 ||| NN
of  ||| S:23 E:26 ||| IN
the  ||| S:26 E:30 ||| DT
MGMT  ||| S:30 E:35 ||| NNP
rs34180180  ||| S:35 E:46 ||| NNP
single-nucleotide  ||| S:46 E:64 ||| JJ
polymorphism  ||| S:64 E:77 ||| NN
in  ||| S:77 E:80 ||| IN
aggressive  ||| S:80 E:91 ||| JJ
gliomas  ||| S:91 E:99 ||| NN
is  ||| S:99 E:102 ||| VBZ
associated  ||| S:102 E:113 ||| VBN
with  ||| S:113 E:118 ||| IN
shorter  ||| S:118 E:126 ||| JJR
patients ||| S:126 E:134 ||| NNS
'  ||| S:134 E:136 ||| POS
survival  ||| S:136 E:145 ||| NN
Malignant  ||| S:145 E:155 ||| NNP
gliomas  ||| S:155 E:163 ||| NNS
are  ||| S:163 E:167 ||| VBP
the  ||| S:167 E:171 ||| DT
most  ||| S:171 E:176 ||| RBS
common  ||| S:176 E:183 ||| JJ
primary  ||| S:183 E:191 ||| JJ
brain  ||| S:191 E:197 ||| NN
tumors ||| S:197 E:203 ||| NNS
.  ||| S:203 E:205 ||| .
Grade  ||| S:205 E:211 ||| NNP
III  ||| S:211 E:215 ||| NNP
and  ||| S:215 E:219 ||| CC
IV  ||| S:219 E:222 ||| NNP
gliomas  ||| S:222 E:230 ||| VBZ
harboring  ||| S:230 E:240 ||| VBG
wild-type  ||| S:240 E:250 ||| JJ
IDH1 ||| S:250 E:254 ||| CD
/ ||| S:254 E:255 ||| CD
2  ||| S:255 E:257 ||| CD
are  ||| S:257 E:261 ||| VBP
the  ||| S:261 E:265 ||| DT
most  ||| S:265 E:270 ||| RBS
aggressive ||| S:270 E:280 ||| JJ
.  ||| S:280 E:282 ||| .
In  ||| S:282 E:285 ||| IN
addition  ||| S:285 E:294 ||| NN
to  ||| S:294 E:297 ||| TO
surgery  ||| S:297 E:305 ||| NN
and  ||| S:305 E:309 ||| CC
radiotherapy ||| S:309 E:321 ||| NN
,  ||| S:321 E:323 ||| ,
concomitant  ||| S:323 E:335 ||| NN
and  ||| S:335 E:339 ||| CC
adjuvant  ||| S:339 E:348 ||| JJ
chemotherapy  ||| S:348 E:361 ||| NN
with  ||| S:361 E:366 ||| IN
temozolomide  ||| S:366 E:379 ||| NNS
( ||| S:379 E:380 ||| -LRB-
TMZ ||| S:380 E:383 ||| NNP
)  ||| S:383 E:385 ||| -RRB-
significantly  ||| S:385 E:399 ||| RB
improves  ||| S:399 E:408 ||| VBZ
overall  ||| S:408 E:416 ||| JJ
survival  ||| S:416 E:425 ||| NN
( ||| S:425 E:426 ||| -LRB-
OS ||| S:426 E:428 ||| NNP
) ||| S:428 E:429 ||| -RRB-
.  ||| S:429 E:431 ||| .
The  ||| S:431 E:435 ||| DT
methylation  ||| S:435 E:447 ||| JJ
status  ||| S:447 E:454 ||| NN
of  ||| S:454 E:457 ||| IN
the  ||| S:457 E:461 ||| DT
O ||| S:461 E:462 ||| NNP
( ||| S:462 E:463 ||| -LRB-
6 ||| S:463 E:464 ||| CD
) ||| S:464 E:465 ||| -RRB-
-methylguanine-DNA  ||| S:465 E:484 ||| JJ
methyltransferase  ||| S:484 E:502 ||| NNS
( ||| S:502 E:503 ||| -LRB-
MGMT ||| S:503 E:507 ||| NNP
)  ||| S:507 E:509 ||| -RRB-
promoter  ||| S:509 E:518 ||| NN
is  ||| S:518 E:521 ||| VBZ
predictive  ||| S:521 E:532 ||| VBN
of  ||| S:532 E:535 ||| IN
TMZ  ||| S:535 E:539 ||| NNP
response  ||| S:539 E:548 ||| NN
and  ||| S:548 E:552 ||| CC
a  ||| S:552 E:554 ||| DT
prognostic  ||| S:554 E:565 ||| JJ
marker  ||| S:565 E:572 ||| NN
of  ||| S:572 E:575 ||| IN
cancer  ||| S:575 E:582 ||| NN
outcome ||| S:582 E:589 ||| NN
.  ||| S:589 E:591 ||| .
However ||| S:591 E:598 ||| RB
,  ||| S:598 E:600 ||| ,
the  ||| S:600 E:604 ||| DT
promoter  ||| S:604 E:613 ||| NN
regions  ||| S:613 E:621 ||| NNS
the  ||| S:621 E:625 ||| DT
methylation  ||| S:625 E:637 ||| NN
of  ||| S:637 E:640 ||| IN
which  ||| S:640 E:646 ||| WDT
correlates  ||| S:646 E:657 ||| VBP
best  ||| S:657 E:662 ||| RB
with  ||| S:662 E:667 ||| IN
survival  ||| S:667 E:676 ||| NN
in  ||| S:676 E:679 ||| IN
aggressive  ||| S:679 E:690 ||| JJ
glioma  ||| S:690 E:697 ||| NN
and  ||| S:697 E:701 ||| CC
whether  ||| S:701 E:709 ||| IN
the  ||| S:709 E:713 ||| DT
promoter  ||| S:713 E:722 ||| FW
methylation  ||| S:722 E:734 ||| FW
status  ||| S:734 E:741 ||| FW
predictive  ||| S:741 E:752 ||| FW
value  ||| S:752 E:758 ||| NN
could  ||| S:758 E:764 ||| MD
be  ||| S:764 E:767 ||| VB
refined  ||| S:767 E:775 ||| VBN
or  ||| S:775 E:778 ||| CC
improved  ||| S:778 E:787 ||| VBN
by  ||| S:787 E:790 ||| IN
other  ||| S:790 E:796 ||| JJ
MGMT-associated  ||| S:796 E:812 ||| JJ
molecular  ||| S:812 E:822 ||| JJ
markers  ||| S:822 E:830 ||| NNS
are  ||| S:830 E:834 ||| VBP
not  ||| S:834 E:838 ||| RB
precisely  ||| S:838 E:848 ||| RB
known ||| S:848 E:853 ||| VBN
.  ||| S:853 E:855 ||| .
In  ||| S:855 E:858 ||| IN
a  ||| S:858 E:860 ||| DT
cohort  ||| S:860 E:867 ||| NN
of  ||| S:867 E:870 ||| IN
87  ||| S:870 E:873 ||| CD
malignant  ||| S:873 E:883 ||| JJ
gliomas  ||| S:883 E:891 ||| NNS
treated  ||| S:891 E:899 ||| VBN
with  ||| S:899 E:904 ||| IN
radiotherapy  ||| S:904 E:917 ||| NN
and  ||| S:917 E:921 ||| CC
TMZ-based  ||| S:921 E:931 ||| JJ
chemotherapy ||| S:931 E:943 ||| NN
,  ||| S:943 E:945 ||| ,
we  ||| S:945 E:948 ||| PRP
retrospectively  ||| S:948 E:964 ||| VBP
determined  ||| S:964 E:975 ||| VBN
the  ||| S:975 E:979 ||| DT
MGMT  ||| S:979 E:984 ||| FW
promoter  ||| S:984 E:993 ||| FW
methylation  ||| S:993 E:1005 ||| FW
status ||| S:1005 E:1011 ||| FW
,  ||| S:1011 E:1013 ||| ,
genotyped  ||| S:1013 E:1023 ||| FW
single  ||| S:1023 E:1030 ||| FW
nucleotide  ||| S:1030 E:1041 ||| FW
polymorphisms  ||| S:1041 E:1055 ||| FW
( ||| S:1055 E:1056 ||| -LRB-
SNPs ||| S:1056 E:1060 ||| NNP
)  ||| S:1060 E:1062 ||| -RRB-
in  ||| S:1062 E:1065 ||| IN
the  ||| S:1065 E:1069 ||| DT
promoter  ||| S:1069 E:1078 ||| NN
region  ||| S:1078 E:1085 ||| NN
and  ||| S:1085 E:1089 ||| CC
quantified  ||| S:1089 E:1100 ||| JJ
MGMT  ||| S:1100 E:1105 ||| NNP
mRNA  ||| S:1105 E:1110 ||| JJ
expression  ||| S:1110 E:1121 ||| NN
level ||| S:1121 E:1126 ||| NN
.  ||| S:1126 E:1128 ||| .
Each  ||| S:1128 E:1133 ||| DT
of  ||| S:1133 E:1136 ||| IN
these  ||| S:1136 E:1142 ||| DT
variables  ||| S:1142 E:1152 ||| NNS
was  ||| S:1152 E:1156 ||| VBD
correlated  ||| S:1156 E:1167 ||| VBN
with  ||| S:1167 E:1172 ||| IN
each  ||| S:1172 E:1177 ||| DT
other  ||| S:1177 E:1183 ||| JJ
and  ||| S:1183 E:1187 ||| CC
with  ||| S:1187 E:1192 ||| IN
the  ||| S:1192 E:1196 ||| DT
patients ||| S:1196 E:1204 ||| NNS
'  ||| S:1204 E:1206 ||| POS
OS ||| S:1206 E:1208 ||| NNP
.  ||| S:1208 E:1210 ||| .
We  ||| S:1210 E:1213 ||| PRP
found  ||| S:1213 E:1219 ||| VBD
that  ||| S:1219 E:1224 ||| DT
methylation  ||| S:1224 E:1236 ||| NN
of  ||| S:1236 E:1239 ||| IN
the  ||| S:1239 E:1243 ||| DT
CpG  ||| S:1243 E:1247 ||| JJ
sites  ||| S:1247 E:1253 ||| NNS
within  ||| S:1253 E:1260 ||| IN
MGMT  ||| S:1260 E:1265 ||| NNP
exon  ||| S:1265 E:1270 ||| VBD
1  ||| S:1270 E:1272 ||| CD
best  ||| S:1272 E:1277 ||| JJS
correlated  ||| S:1277 E:1288 ||| NN
with  ||| S:1288 E:1293 ||| IN
OS  ||| S:1293 E:1296 ||| NNP
and  ||| S:1296 E:1300 ||| CC
MGMT  ||| S:1300 E:1305 ||| NNP
expression  ||| S:1305 E:1316 ||| NN
levels ||| S:1316 E:1322 ||| NNS
,  ||| S:1322 E:1324 ||| ,
and  ||| S:1324 E:1328 ||| CC
confirmed  ||| S:1328 E:1338 ||| VBD
MGMT  ||| S:1338 E:1343 ||| NNP
methylation  ||| S:1343 E:1355 ||| NN
as  ||| S:1355 E:1358 ||| IN
a  ||| S:1358 E:1360 ||| DT
stronger  ||| S:1360 E:1369 ||| JJR
independent  ||| S:1369 E:1381 ||| JJ
prognostic  ||| S:1381 E:1392 ||| JJ
factor  ||| S:1392 E:1399 ||| NN
compared  ||| S:1399 E:1408 ||| VBN
to  ||| S:1408 E:1411 ||| TO
MGMT  ||| S:1411 E:1416 ||| NNP
transcription  ||| S:1416 E:1430 ||| NN
levels ||| S:1430 E:1436 ||| NNS
.  ||| S:1436 E:1438 ||| .
Our  ||| S:1438 E:1442 ||| PRP$
main  ||| S:1442 E:1447 ||| JJ
finding  ||| S:1447 E:1455 ||| NN
is  ||| S:1455 E:1458 ||| VBZ
that  ||| S:1458 E:1463 ||| IN
the  ||| S:1463 E:1467 ||| DT
presence  ||| S:1467 E:1476 ||| NN
of  ||| S:1476 E:1479 ||| IN
only  ||| S:1479 E:1484 ||| RB
the  ||| S:1484 E:1488 ||| DT
A  ||| S:1488 E:1490 ||| DT
allele  ||| S:1490 E:1497 ||| NN
at  ||| S:1497 E:1500 ||| IN
the  ||| S:1500 E:1504 ||| DT
rs34180180  ||| S:1504 E:1515 ||| NNP
SNP  ||| S:1515 E:1519 ||| NNP
in  ||| S:1519 E:1522 ||| IN
the  ||| S:1522 E:1526 ||| DT
tumor  ||| S:1526 E:1532 ||| NN
was  ||| S:1532 E:1536 ||| VBD
significantly  ||| S:1536 E:1550 ||| RB
associated  ||| S:1550 E:1561 ||| VBN
with  ||| S:1561 E:1566 ||| IN
shorter  ||| S:1566 E:1574 ||| JJR
OS ||| S:1574 E:1576 ||| NNP
,  ||| S:1576 E:1578 ||| ,
independently  ||| S:1578 E:1592 ||| RB
of  ||| S:1592 E:1595 ||| IN
the  ||| S:1595 E:1599 ||| DT
MGMT  ||| S:1599 E:1604 ||| FW
methylation  ||| S:1604 E:1616 ||| FW
status ||| S:1616 E:1622 ||| FW
.  ||| S:1622 E:1624 ||| .
In  ||| S:1624 E:1627 ||| IN
conclusion ||| S:1627 E:1637 ||| NN
,  ||| S:1637 E:1639 ||| ,
in  ||| S:1639 E:1642 ||| IN
the  ||| S:1642 E:1646 ||| DT
clinic ||| S:1646 E:1652 ||| NN
,  ||| S:1652 E:1654 ||| ,
rs34180180  ||| S:1654 E:1665 ||| NNP
SNP  ||| S:1665 E:1669 ||| NNP
genotyping  ||| S:1669 E:1680 ||| NN
could  ||| S:1680 E:1686 ||| MD
improve  ||| S:1686 E:1694 ||| VB
the  ||| S:1694 E:1698 ||| DT
prognostic  ||| S:1698 E:1709 ||| JJ
value  ||| S:1709 E:1715 ||| NN
of  ||| S:1715 E:1718 ||| IN
the  ||| S:1718 E:1722 ||| DT
MGMT  ||| S:1722 E:1727 ||| NNP
promoter  ||| S:1727 E:1736 ||| NN
methylation  ||| S:1736 E:1748 ||| NN
assay  ||| S:1748 E:1754 ||| NN
in  ||| S:1754 E:1757 ||| IN
patients  ||| S:1757 E:1766 ||| NNS
with  ||| S:1766 E:1771 ||| IN
aggressive  ||| S:1771 E:1782 ||| JJ
glioma  ||| S:1782 E:1789 ||| NNS
treated  ||| S:1789 E:1797 ||| VBN
with  ||| S:1797 E:1802 ||| IN
TMZ ||| S:1802 E:1805 ||| NNP
.  ||| S:1805 E:1807 ||| .
